ImpriMed to Present Ex Vivo Drug Sensitivity Data in Acute Myeloid Leukemia in Oral Presentation at American Society of Hematology Annual Meeting
Studies Demonstrate xCellSense® Platform's Ability to Predict Clinical Response and Enable Patient Stratification for Drug Development. PALO ALTO, Calif., Dec. 4, 2025 /PRNewswire/ -- ImpriMed, a precision oncology CRO specializing in ex vivo drug...